Medicare AdvantageAdministrativeLow impact
MA06.014e, Pharmacogenetics and Metabolite Monitoring for Using Azathioprine (AZA)/6-Mercaptopurine (6-MP) Therapy
Independence Blue Cross·NJ · Gastroenterology, Rheumatology, Hematology +3 more·Medical Policy
We identified it
Jun 19, 2026
Summary
This is a reissue with no substantive changes to MA06.014e, a Medicare Advantage policy covering pharmacogenetic testing (TPMT genotyping/phenotyping) and metabolite monitoring for azathioprine/6-mercaptopurine therapy. The policy remains unchanged in coverage criteria, but CPT code 84433 was added to the policy documentation as of the most recent revision (09/16/2026).
Action Required
No immediate billing workflow changes required. Billing team should verify that billing system reflects the following codes for TPMT testing and metabolite monitoring: CPT 81401 (genotyping), CPT 82542 and 82657 (phenotyping), CPT 84433 (metabolite monitoring), and HCPCS G0452 (physician interpretation). Ensure prior authorization or documentation requirements are in place for these services when billed to Independence Blue Cross Medicare Advantage plans. Confirm that claims include medical necessity documentation demonstrating TPMT screening before AZA/6-MP initiation or post-initiation monitoring for toxicity assessment/dose optimization.